Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MEGAN S DEVINE

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1255541108
CMS profile
283573
Location
TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,031.70

86 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,931.71 85
Education $99.99 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MEGAN S DEVINE

NPI 1255541108 · CMS profile ID 283573

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255541108?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MEGAN S DEVINE, NPI 1255541108, CMS profile ID 283573. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255541108?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MEGAN S DEVINE, NPI 1255541108, CMS profile ID 283573. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255541108?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MEGAN S DEVINE, NPI 1255541108, CMS profile ID 283573, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1255541108?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

86 matching records · $2,031.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 86 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–86 of 86.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $14.3507/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190842797 CMS
GlaxoSmithKline, LLC. $11.5706/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191507226 CMS
Boston Scientific Corporation $94.4106/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181193382 CMS
Boston Scientific Corporation $8.6406/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181193378 CMS
GlaxoSmithKline, LLC. $15.3406/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190692208 CMS
GlaxoSmithKline, LLC. $14.1506/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190763437 CMS
GlaxoSmithKline, LLC. $4.5406/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191168383 CMS
GlaxoSmithKline, LLC. $15.1205/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190338395 CMS
Grifols Shared Services North America, Inc. $35.0005/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249580840 CMS
VERTEX PHARMACEUTICALS INCORPORATED $19.4505/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213878474 CMS
Boston Scientific Corporation $6.4505/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181193380 CMS
Insmed, Inc. $17.9505/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186267202 CMS
GlaxoSmithKline, LLC. $8.7005/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191836510 CMS
Baxter Healthcare $24.6005/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181701221 CMS
Baxter Healthcare $15.8604/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181701219 CMS
AstraZeneca Pharmaceuticals LP $18.3304/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207253869 CMS
Viatris Specialty LLC $23.5404/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238504715 CMS
Merck Sharp & Dohme LLC $20.4704/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238325256 CMS
GENZYME CORPORATION $31.7804/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233422592 CMS
GlaxoSmithKline, LLC. $14.0004/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191224298 CMS
Aimmune Therapeutics, Inc. $23.5004/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249684528 CMS
GENZYME CORPORATION $30.4303/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233422572 CMS
GlaxoSmithKline, LLC. $10.5503/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190693552 CMS
GlaxoSmithKline, LLC. $15.3103/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190639507 CMS
AstraZeneca Pharmaceuticals LP $18.3803/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207092169 CMS
GENZYME CORPORATION $20.8302/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233422556 CMS
ABBVIE INC. $20.5902/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201758192 CMS
GlaxoSmithKline, LLC. $15.7902/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190849024 CMS
AstraZeneca Pharmaceuticals LP $17.8402/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206926839 CMS
GlaxoSmithKline, LLC. $17.0002/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190799484 CMS
Actelion Pharmaceuticals US, Inc. $32.3201/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174309377 CMS
Electromed, Inc. $2.1601/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224588664 CMS
Electromed, Inc. $18.6101/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224588669 CMS
VERTEX PHARMACEUTICALS INCORPORATED $19.5201/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213890315 CMS
Philips North America LLC $15.5001/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232601638 CMS
GlaxoSmithKline, LLC. $13.9801/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190830110 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,775.02 14
PY2020 $313.74 17
PY2021 $160.32 10
PY2022 $470.56 33
PY2023 $555.41 32
PY2024 $1,519.28 67
PY2025 $2,031.70 86

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $194,337.54 92
PY2024 Principal investigator $69,784.00 11
PY2023 Principal investigator $26,498.00 4
PY2021 Principal investigator $5,599.80 1
PY2020 Principal investigator $3,700.00 2
PY2019 Principal investigator $17.20 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

92 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 12/17/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620042
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 12/17/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620044
Principal investigator 1 Boehringer Ingelheim International GmbH $2.32 12/17/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620046
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 12/17/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620048
Principal investigator 2 Mannkind Corporation $10,000.00 12/10/2025 Non-covered Recipient Entity
UT HEALTH SCIENCE CENTER
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898690
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,151.80 12/05/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220795803
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 12/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620028
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 12/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620030
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 12/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620032
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 12/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620034
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 12/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670252
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 12/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670254
Principal investigator 1 Verona Pharma, Inc. $1,500.00 12/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH
Verona No dispute reported 06/30/2026 1232891417
Principal investigator 1 Verona Pharma, Inc. $736.54 12/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH
Verona No dispute reported 06/30/2026 1232891419
Principal investigator 1 Boehringer Ingelheim International GmbH $2.50 11/28/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620050
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 11/28/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620052
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 11/28/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620054
Principal investigator 1 Boehringer Ingelheim International GmbH $0.87 11/20/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620002
Principal investigator 1 Boehringer Ingelheim International GmbH $4.72 11/20/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620004
Principal investigator 1 Boehringer Ingelheim International GmbH $0.70 11/20/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620006
Principal investigator 1 Boehringer Ingelheim International GmbH $9.60 11/20/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620008
Principal investigator 1 Boehringer Ingelheim International GmbH $11.39 11/20/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620010
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 11/19/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620036
Principal investigator 1 Boehringer Ingelheim International GmbH $2.32 11/19/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620038
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 11/19/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620040
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 11/19/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670256
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 11/19/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670258
Principal investigator 1 Boehringer Ingelheim International GmbH $1.41 11/19/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670260
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,668.10 11/17/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220795801
Principal investigator 1 Verona Pharma, Inc. $11,654.77 11/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH
Verona No dispute reported 06/30/2026 1232891413
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 11/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620020
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 11/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620022
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 11/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620024
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 11/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620026
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 11/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670248
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 11/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670250
Principal investigator 1 SANOFI US SERVICES INC. $11,194.00 10/27/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226120392
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,382.30 10/22/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220795799
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 10/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620012
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 10/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620014
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 10/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620016
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 10/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620018
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 10/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670244
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 10/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670246
Principal investigator 1 Genentech, Inc. $1,250.00 10/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211562922
Principal investigator 1 Genentech, Inc. $3,300.00 10/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211562925
Principal investigator 1 SANOFI US SERVICES INC. $420.00 09/15/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226120381
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 09/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619972
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 09/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619996
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 09/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619998
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 09/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220620000
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 09/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670238
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 09/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670240
Principal investigator 1 SANOFI US SERVICES INC. $47,704.00 08/25/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226120384
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 08/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619978
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 08/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619986
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 08/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619988
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 08/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619990
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619992
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619994
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 08/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670234
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 08/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670236
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 07/28/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670242
Principal investigator 1 Boehringer Ingelheim International GmbH $799.00 07/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619970
Principal investigator 1 Boehringer Ingelheim International GmbH $32.94 07/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619974
Principal investigator 1 Boehringer Ingelheim International GmbH $120.93 07/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619976
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 07/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619980
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 07/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619982
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 07/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619984
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 07/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670230
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 07/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670232
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,000.00 06/25/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220795795
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $203.88 06/05/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220795797
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,000.00 06/04/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids No dispute reported 06/30/2026 1185546795
Principal investigator 1 Verona Pharma, Inc. $3,500.00 06/02/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Verona No dispute reported 06/30/2026 1232891835
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 06/01/2025 Non-covered Recipient Entity
UNIV OF TEXAS HSC ATTY TYLER
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220619968
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 06/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670226
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 06/01/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220670228
Principal investigator 1 Genentech, Inc. $1,025.00 05/16/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211562914
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,928.70 05/06/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220795793
Principal investigator 1 Genentech, Inc. $4,100.00 04/25/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211562910
Principal investigator 1 Verona Pharma, Inc. $13,000.00 04/25/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Verona No dispute reported 06/30/2026 1232891831
Principal investigator 1 Genentech, Inc. $1,025.00 04/11/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211562906
Principal investigator 1 Genentech, Inc. $1,025.00 04/04/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211562917
Principal investigator 1 Genentech, Inc. $2,050.00 03/21/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211562871
Principal investigator 1 Genentech, Inc. $1,025.00 03/07/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211562855
Principal investigator 1 Genentech, Inc. $500.00 02/26/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211562863
Principal investigator 1 Genentech, Inc. $1,025.00 02/05/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211562867
Principal investigator 2 Mannkind Corporation $22,500.00 02/05/2025 Non-covered Recipient Entity
UT HEALTH SCIENCE CENTER
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898426
Principal investigator 2 Mannkind Corporation $3,500.00 02/05/2025 Non-covered Recipient Entity
UT HEALTH SCIENCE CENTER
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898428
Principal investigator 1 Genentech, Inc. $3,636.00 01/29/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211562859
Principal investigator 1 Genentech, Inc. $8,200.00 01/13/2025 Covered Recipient Teaching Hospital
Ut Health Center At Tyler
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211562874